Get the Stockscreener App
7.99
0.13%
0.010
After Hours:
7.99
Puma Biotechnology Inc stock is traded at $7.99, with a volume of 143.87K.
It is up +0.13% in the last 24 hours and down -1.48% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$7.98
Open:
$8.04
24h Volume:
143.87K
Relative Volume:
0.48
Market Cap:
$406.69M
Revenue:
$227.18M
Net Income/Loss:
$24.38M
P/E Ratio:
16.74
EPS:
0.4774
Net Cash Flow:
$53.60M
1W Performance:
-3.73%
1M Performance:
-1.48%
6M Performance:
+21.61%
1Y Performance:
+143.60%
1-Day Range:
$7.99
$8.18
1-Week Range:
$7.61
$8.75
52-Week Range:
$3.03
$8.75
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.99 | 406.18M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Puma Biotechnology Inc (PBYI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Puma Biotechnology Inc (PBYI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ETFs Investing in Puma Biotechnology, Inc. Stocks - TradingView
PBYI|Puma Biotechnology Inc|Price:7.980|Chg%:-0.030 - TradingKey
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results - WBOC TV
Puma Biotechnology schedules conference call on Q2 2026 results - Bitget
Puma Stock Puma Biotechnology Inc Discount Puma Biotechnology Acquisition Outlet Online PUMA Biotechnology Form S - มูลนิธิเพื่อผู้บริโภค มพบ.
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares By Investing.com - Investing.com Nigeria
Puma biotechnology CFO Maximo Nougues sells $77,556 in stock By Investing.com - Investing.com South Africa
Form 4 Puma Biotechnology Inc For: 8 July By Investing.com - Investing.com Nigeria
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com - Investing.com South Africa
Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan
Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 - Investing.com
Form 144 PUMA BIOTECHNOLOGY For: 6 July By Investing.com - Investing.com Nigeria
[144] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Price to sales forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
PBYIPuma Biotechnology Inc Latest SEC Filings - Finviz
Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI - Ad-hoc-news.de
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 - BioSpace
PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
Puma Biotechnology awards stock to four new employees - Stock Titan
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2000 Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to revenue forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBITDA forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
PBYI Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBIT forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBITDA forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI) - TradingView
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates - Kavout | AI
Puma Pharmaceuticals Puma Biotechnology Puma Biotechnology Puma 2019 Revenue Breast Cancer Treatment - consumerthai
Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Puma Biotechnology Inc (PBYI) Institutional Confidence - TradingKey
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Pharmaceuticals Clinical Trials Puma Biotechnology Mountain Lion Puma Concolor Lounging By Gerry Ellis - consumerthai
Puma Biotechnology Inc (PBYI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Puma Biotechnology Inc (PBYI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Puma Biotechnology StockShareholders back board but reject warrant extension - AD HOC NEWS
Puma Biotechnology shareholders elect directors and vote on key proposals - Investing.com UK
Puma Biotechnology shareholders elect directors and vote on key proposals By Investing.com - Investing.com South Africa
Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension - TipRanks
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):